BACKGROUND: Tumor content in circulating cell-free DNA (cfDNA) is a promising biomarker, but longitudinal dynamics of tumor-derived and non-tumor-derived cfDNA through multiple courses of therapy have not been well described. METHODS: CfDNA from 663 plasma samples from 140 patients with castration-resistant prostate cancer (CRPC) was subject to sparse whole genome sequencing. Tumor fraction (TFx) estimated using the computational tool ichorCNA was correlated with clinical features and responses to therapy. RESULTS: TFx associated with the number of bone metastases (median TFx = 0.014 with no bone metastases, 0.047 with 1-3 bone metastases, 0.190 for 4+ bone metastases; P < 0.0001) and with visceral metastases (P < 0.0001). In multivariable analysis, TFx remained associated with metastasis location (P = 0.042); TFx was positively correlated with alkaline phosphatase (P = 0.0227) and negatively correlated with hemoglobin (Hgb) (P < 0.001), but it was not correlated with prostate specific antigen (PSA) (P = 0.75). Tumor-derived and non-tumor-derived cfDNA track together and do not increase with generalized tissue damage from chemotherapy or radiation at the time scales examined. All new treatments that led to ≥30% PSA decline at 6 weeks were associated with TFx decline when baseline TFx was >7%; however, TFx in patients being subsequently maintained on secondary hormonal therapy was quite dynamic. CONCLUSION: TFx correlates with clinical features associated with overall survival in CRPC, and TFx decline is a promising biomarker for initial therapeutic response. TRIAL REGISTRATION: Dana-Farber/Harvard Cancer Center (DF/HCC) protocol no. 18-135. FUNDING: Wong Family Award in Translational Oncology, Dana Farber Cancer Institute Medical Oncology grant, Gerstner Family Foundation, Janssen Pharmaceuticals Inc., and Koch Institute Support (core) grant P30-CA14051 from the National Cancer Institute (NCI).
BACKGROUND: Tumor content in circulating cell-free DNA (cfDNA) is a promising biomarker, but longitudinal dynamics of tumor-derived and non-tumor-derived cfDNA through multiple courses of therapy have not been well described. METHODS: CfDNA from 663 plasma samples from 140 patients with castration-resistant prostate cancer (CRPC) was subject to sparse whole genome sequencing. Tumor fraction (TFx) estimated using the computational tool ichorCNA was correlated with clinical features and responses to therapy. RESULTS: TFx associated with the number of bone metastases (median TFx = 0.014 with no bone metastases, 0.047 with 1-3 bone metastases, 0.190 for 4+ bone metastases; P < 0.0001) and with visceral metastases (P < 0.0001). In multivariable analysis, TFx remained associated with metastasis location (P = 0.042); TFx was positively correlated with alkaline phosphatase (P = 0.0227) and negatively correlated with hemoglobin (Hgb) (P < 0.001), but it was not correlated with prostate specific antigen (PSA) (P = 0.75). Tumor-derived and non-tumor-derived cfDNA track together and do not increase with generalized tissue damage from chemotherapy or radiation at the time scales examined. All new treatments that led to ≥30% PSA decline at 6 weeks were associated with TFx decline when baseline TFx was >7%; however, TFx in patients being subsequently maintained on secondary hormonal therapy was quite dynamic. CONCLUSION: TFx correlates with clinical features associated with overall survival in CRPC, and TFx decline is a promising biomarker for initial therapeutic response. TRIAL REGISTRATION: Dana-Farber/Harvard Cancer Center (DF/HCC) protocol no. 18-135. FUNDING: Wong Family Award in Translational Oncology, Dana Farber Cancer Institute Medical Oncology grant, Gerstner Family Foundation, Janssen Pharmaceuticals Inc., and Koch Institute Support (core) grant P30-CA14051 from the National Cancer Institute (NCI).
Authors: Jenny H Lee; Georgina V Long; Alexander M Menzies; Serigne Lo; Alexander Guminski; Kataraina Whitbourne; Michelle Peranec; Richard Scolyer; Richard F Kefford; Helen Rizos; Matteo S Carlino Journal: JAMA Oncol Date: 2018-05-01 Impact factor: 31.777
Authors: Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono Journal: N Engl J Med Date: 2012-08-15 Impact factor: 91.245
Authors: Roni Lehmann-Werman; Daniel Neiman; Hai Zemmour; Joshua Moss; Judith Magenheim; Adi Vaknin-Dembinsky; Sten Rubertsson; Bengt Nellgård; Kaj Blennow; Henrik Zetterberg; Kirsty Spalding; Michael J Haller; Clive H Wasserfall; Desmond A Schatz; Carla J Greenbaum; Craig Dorrell; Markus Grompe; Aviad Zick; Ayala Hubert; Myriam Maoz; Volker Fendrich; Detlef K Bartsch; Talia Golan; Shmuel A Ben Sasson; Gideon Zamir; Aharon Razin; Howard Cedar; A M James Shapiro; Benjamin Glaser; Ruth Shemer; Yuval Dor Journal: Proc Natl Acad Sci U S A Date: 2016-03-14 Impact factor: 11.205
Authors: Himisha Beltran; Scott Tomlins; Ana Aparicio; Vivek Arora; David Rickman; Gustavo Ayala; Jiaoti Huang; Lawrence True; Martin E Gleave; Howard Soule; Christopher Logothetis; Mark A Rubin Journal: Clin Cancer Res Date: 2014-04-11 Impact factor: 12.531
Authors: Juozas Gordevičius; Algimantas Kriščiūnas; Daniel E Groot; Steven M Yip; Miki Susic; Andrew Kwan; Rafal Kustra; Anthony M Joshua; Kim N Chi; Art Petronis; Gabriel Oh Journal: Clin Cancer Res Date: 2018-04-03 Impact factor: 12.531
Authors: Viktor A Adalsteinsson; Gavin Ha; Samuel S Freeman; Atish D Choudhury; Daniel G Stover; Heather A Parsons; Gregory Gydush; Sarah C Reed; Denisse Rotem; Justin Rhoades; Denis Loginov; Dimitri Livitz; Daniel Rosebrock; Ignaty Leshchiner; Jaegil Kim; Chip Stewart; Mara Rosenberg; Joshua M Francis; Cheng-Zhong Zhang; Ofir Cohen; Coyin Oh; Huiming Ding; Paz Polak; Max Lloyd; Sairah Mahmud; Karla Helvie; Margaret S Merrill; Rebecca A Santiago; Edward P O'Connor; Seong H Jeong; Rachel Leeson; Rachel M Barry; Joseph F Kramkowski; Zhenwei Zhang; Laura Polacek; Jens G Lohr; Molly Schleicher; Emily Lipscomb; Andrea Saltzman; Nelly M Oliver; Lori Marini; Adrienne G Waks; Lauren C Harshman; Sara M Tolaney; Eliezer M Van Allen; Eric P Winer; Nancy U Lin; Mari Nakabayashi; Mary-Ellen Taplin; Cory M Johannessen; Levi A Garraway; Todd R Golub; Jesse S Boehm; Nikhil Wagle; Gad Getz; J Christopher Love; Matthew Meyerson Journal: Nat Commun Date: 2017-11-06 Impact factor: 14.919
Authors: Mary E Kim; Liya Xu; Rishvanth K Prabakar; Lishuang Shen; Chen-Ching Peng; Peter Kuhn; Xiaowu Gai; James Hicks; Jesse L Berry Journal: J Vis Exp Date: 2021-09-07 Impact factor: 1.424
Authors: Heather A Parsons; Justin Rhoades; Sarah C Reed; Gregory Gydush; Priyanka Ram; Pedro Exman; Kan Xiong; Christopher C Lo; Tianyu Li; Mark Fleharty; Gregory J Kirkner; Denisse Rotem; Ofir Cohen; Fangyan Yu; Mariana Fitarelli-Kiehl; Ka Wai Leong; Melissa E Hughes; Shoshana M Rosenberg; Laura C Collins; Kathy D Miller; Brendan Blumenstiel; Lorenzo Trippa; Carrie Cibulskis; Donna S Neuberg; Matthew DeFelice; Samuel S Freeman; Niall J Lennon; Nikhil Wagle; Gavin Ha; Daniel G Stover; Atish D Choudhury; Gad Getz; Eric P Winer; Matthew Meyerson; Nancy U Lin; Ian Krop; J Christopher Love; G Mike Makrigiorgos; Ann H Partridge; Erica L Mayer; Todd R Golub; Viktor A Adalsteinsson Journal: Clin Cancer Res Date: 2020-03-13 Impact factor: 12.531
Authors: Liya Xu; Lishuang Shen; Ashley Polski; Rishvanth K Prabakar; Rachana Shah; Rima Jubran; Jonathan W Kim; Jacklyn Biegel; Peter Kuhn; David Cobrinik; James Hicks; Xiaowu Gai; Jesse L Berry Journal: Ophthalmic Genet Date: 2020-08-17 Impact factor: 1.803
Authors: Stephen J Bagley; S Ali Nabavizadeh; Jazmine J Mays; Jacob E Till; Jeffrey B Ware; Scott Levy; Whitney Sarchiapone; Jasmin Hussain; Timothy Prior; Samantha Guiry; Theresa Christensen; Stephanie S Yee; MacLean P Nasrallah; Jennifer J D Morrissette; Zev A Binder; Donald M O'Rourke; Andrew J Cucchiara; Steven Brem; Arati S Desai; Erica L Carpenter Journal: Clin Cancer Res Date: 2019-10-30 Impact factor: 12.531
Authors: Ruben Van Paemel; Andries De Koker; Charlotte Vandeputte; Lieke van Zogchel; Tim Lammens; Geneviève Laureys; Jo Vandesompele; Gudrun Schleiermacher; Mathieu Chicard; Nadine Van Roy; Ales Vicha; G A M Tytgat; Nico Callewaert; Katleen De Preter; Bram De Wilde Journal: Epigenetics Date: 2020-07-14 Impact factor: 4.528
Authors: Shuo Li; Zorawar S Noor; Weihua Zeng; Mary L Stackpole; Xiaohui Ni; Yonggang Zhou; Zuyang Yuan; Wing Hung Wong; Vatche G Agopian; Steven M Dubinett; Frank Alber; Wenyuan Li; Edward B Garon; Xianghong Jasmine Zhou Journal: Nat Commun Date: 2021-07-07 Impact factor: 14.919